One of the doctors’ headaches when treating patients with covid-19 is determining which ones had a higher risk of progressing negatively and being attacked by the ‘cytokine storm’ that can end up killing the patient.
Now, a team of French researchers, after studying 50 patients with covid-19, have identified a unique ‘footprint’, which is a combination of deficiency in the response of a particular interferon, as well as exacerbated inflammation, in more patients. serious.
In his work, which is published in « Science»They propose that this signature or imprint may be a hallmark of severe covid-19 and provides specialists with a rationale for initiating therapeutic approaches that combine supplementation with interferon with neutralization of inflammatory signaling.
The covid-19 is characterized by different patterns of disease progression depending on the patient, which implies that each subject exhibits different immune responses to the SARS-Cov-2 coronavirus.
So far, studies suggest that 5-10% of patients progress to serious or critical illness. However, little is known about the immunological characteristics involved in the severity of covid-19.
Critically ill patients exhibited a distinctive double signature that implies a deficiency in the responses of type I interferons, proteins that help fight viral infections, as well as exacerbated proinflammatory signaling.
While recent work to investigate the role of interferon signaling in covid-19 patients has shown that local interferon signaling may be important in mitigating disease progression, the results of this work suggest that a larger production of interferons, in fact, may be beneficial.
The work reinforces a growing hypothesis that suggests the location, timing, and duration of interferon exposure are critical parameters underlying the success of therapeutics for SARS-CoV-2 infections.
The researchers also believe that seriously ill covid-19 patients could be treated with a combined approach focused on interferon administration and tailored anti-inflammatory therapies, “a hypothesis worth doing cautious testing,” they say.